Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Shahid Beheshti University of Medical Sciences

Status and phase: Unknown; Phase 3

Conditions: Neovascular Age-Related Macular Degeneration

Treatments: Drug: bevacizumab + triamcinolone acetonide; Drug: bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00370370

8533

Details and patient eligibility

About

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion criteria

• History of glaucoma or ocular hypertension
• Disciform scar

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

0 participants in 2 patient groups

1

Active Comparator group

Description:

Injection of intravitreal bevacizumab

Treatment:

Drug: bevacizumab

2

Active Comparator group

Description:

Injection of bevacizumab + triamcinolone acetonide

Treatment:

Drug: bevacizumab + triamcinolone acetonide